Compare AVLN & TBLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | TBLA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2026 | 2021 |
| Metric | AVLN | TBLA |
|---|---|---|
| Price | $27.52 | $3.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $62.25 | $5.80 |
| AVG Volume (30 Days) | 192.8K | ★ 1.5M |
| Earning Date | 08-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 220.00 |
| Revenue | N/A | ★ $1,912,040,000.00 |
| Revenue This Year | N/A | $1.65 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | ★ N/A | $0.02 |
| Revenue Growth | N/A | ★ 8.26 |
| 52 Week Low | $24.90 | $2.84 |
| 52 Week High | $40.17 | $5.71 |
| Indicator | AVLN | TBLA |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 32.16 |
| Support Level | $25.86 | $2.97 |
| Resistance Level | $30.45 | $3.47 |
| Average True Range (ATR) | 2.25 | 0.12 |
| MACD | -0.56 | -0.01 |
| Stochastic Oscillator | 14.12 | 5.08 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.